Rexahn Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rexahn.com
Clinical Trials
8
Active:0
Completed:6
Trial Phases
2 Phases
Phase 1:2
Phase 2:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (75.0%)Phase 1
2 (25.0%)Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02089334
- Locations
- 🇺🇸
Rexahn Site, Seattle, Washington, United States
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02003092
- Locations
- 🇺🇸
Rexahn site, Arlington, Virginia, United States
🇺🇸Rexahn Site, Greenville, South Carolina, United States
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT01273376
- Locations
- 🇺🇸
Rexahn Investigative Site, Bellevue, Washington, United States
🇺🇸Rexahn Investigative Site -2, Atlanta, Georgia, United States
🇺🇸Rexahn Investigative site, Dallas, Texas, United States
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Drug: RX-0201 plus Gemcitabine
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01028495
- Locations
- 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Orchard Healthcare Research Inc., Skokie, Illinois, United States
🇺🇸Texas Oncology, Austin, Texas, United States
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT00839176
- Prev
- 1
- 2
- Next
News
No news found